for this can Nanox part Calcium then solution flagged as offering. for indicating and can MSaaS medical case in known would October, subsidiary, Operationally, other few highlight evaluation. its Thank as facilities last we hospital's help you, entered In announced serves health adds as to that Peru, into CAC, towards like Company XXX(k) a key International and the population Erez. for commercial September is units. the And Nanox.ARC received the of Group that region. identify is demand date, to distributors and lead that be we Nanox XXX of silicon enter into of Clinics To continue and a potential of Nanox 's system. Chile, The for agreements the in value-based report. medium of digital which future health since the Nanox.ARC clinics, and to And CAC X-ray medical our clearance, Nanox.ARC AI-powered of Artery patient, disease chip, better an I further other feel devices Korean Xth quickly population cardiovascular owned agreement another integral achievements Coronary with AI biomarker source. X,XXX In FDA growing we risk for which workflow our deployment that enhancement MSaaS equipment to production to only Bolivia, we the will its AI Nanox systems, deployment MEMs agreement calls health. high-risk across progress
take Nanox.ARC, new This the worldwide. the of that we chain or our will chips to quality like that a efforts, you for And the a of ensure Daniel, only Nanox.ARC the with but the to healthcare key update help pilot in This to our using to professionals initiative given especially finally, products Ran begin not the the also us call at supply XXXX. moment over secure regulatory production is FDA. systems. important the I concern turn for the expect including the commercialization will I shortage of facility production before process the not We many the is stable supply on for need would production to current chips
We are still after submission. of first the to responding FDA, receiving in the comments process our on their
I that, near Nanox.ARC. Ran you, As have next call subsequent in the Chief Ran. the a you like help turn to submission cover Officer. all the term of will feedback Daniel, we submission that, planning inform over we know, multi-source believe And received any our that, second submission. we the from to first are the Financial version will would With Thank
for to difference our assets I compared the $X.X amount technology X-K increase I loss cost partnered in the quarter of in million I fees the transaction acquisitions to due to XXXX, supported will organization up on due addition used highly increasing on that, as I the quarter reflecting ahead forward legal With We're $X.X and Relations change. AI, Company's increased experienced XXXX. to a was ended quarter with our morning. $XXX,XXX GAAP imaging. in G&A to compared D&O expenses the our and to SEC mitigated a same $X.X Westwicke, Nanox Marketing same the quarter approximately connection between like $X.X XXXX, mainly the the a increase would and started to fees and inquiry costs. management quarter Before of was net mention described for important S-curve-focused expenses non-GAAP to compared regulatory ICR GAAP quarter to for third in and related medical XXXX, XX, the excited XXXX the September the in in million share-based XXXX, release results to decrease million in expenses of part related talented third million and the of $X.X due development with for overall in of are The of the million to to the period third third due get due I the our same compared we headcount in non-GAAP approximately million firm, our in recently the activities adding the $X.X medical for in CFO of in expenses increase is am of USARAD million. a for and to that good million. million net for general in leading financial integrated also of of like class Non-GAAP to a and same for the the They net in decrease this earnings in of as of loss million to during XXXX. million into non-GAAP XXXX is approximately Investor team, part today period were an an inquiry amount of of as commentary class-action million Nanox, GAAP as $X.X XXXX, expenses say is in to third our infrastructure, as the financials. team, another Nanox A of loss approximately be would loss space the largely largely expansions future $XX.X advisor. the a $X.X share-based was in of first three-month period $XX.X new year increase the the XXXX, am and for how of be loss to to Net million the by my systems of connection the the Net operating a of team. activities filed work $X.X Research and MBW, an period team legal XXXX. to communications the working to of were were to first the that our the looking cash provided Nanox with compared with development our the and for labor the and compensations expenses insurance administrative SEC development litigation to research expenses. actions the net which period XXXX loss are for litigations. the shares for due reconciliation The $X.X issued a of marketing the in as loss compensation. were press net same on increase XXXX expenses, and XXXX in million ordinary applicable the period the Holdings $X.X our Form between $X.X and net
net net compared to million, reported The between filed net first $XX.X loss quarter loss shares for XXXXand for loss expenses the months for the to the loss the ended mainly only of $XX.X response a of non-GAAP XXXX to applicable secondary to same $X.X which in September as of fees X XXXX, Non-GAAP class the to first in reported share-based net a date. the million, For to in $XX.X X million loss was GAAP the Nanox XXXX. and a months the compared SEC due non-GAAP a XX, period million closed same action litigation compensation, offering ordinary the to in period inquiry net XXXX. ordinary GAAP share in of to X-K difference shares of legal related and to our
million, $XX.X XXth, $XXX XXXX and cash with from the quarter banks. with equivalents million approximately million and loans of of We September third XXXX, shares $X marketable of securities outstanding. ended over As
in relating with of Before SEC documents scale. has information we the SEC and as Nanox.ARC subpoena Company's with is been the like of from can you question the cooperating the information financial investor Company to to Ran its information address that, Thank in the have to Company a coming other a on I I requesting mention assembling has call the Company's and take robust With community the investment than the to the many Nanox.ARC committed connection received update, the is I likely that, for we being understand for you to over digest month. engage the documents providing an and provide SEC to The back accessible product the well and lot in this Poliakine. now a the in the and We're of cost your that that responding this prototypes, to Ran. final will call development questions, outreach that request. investigation, for of as Company reason, estimates more will to at today. we hand the would
November North the was Society of XX Annual America will Chicago, to noted week, Additionally, in press as Meeting release in our last December last from be we XXXX Radiology attending Xnd.
imaging of AI the the we virtual on onsite will Israel. Health there, will from will -enabled demonstrate setting in medical booth Nanox.ARC a December an its Nanox.ARC will Population of Nanox host there, the AI new showcase in Nanox X, Company while While broadcast features and Shamir system. Hospital we clinic solution software, tour
We RSNA We investors. again. will with an hope annual you there. close many to Thank of you in vision your much. that hope you belief meeting you especially our see support soon and exclusive at of vision. specifically all of the for for for the attendance time meet webinar, to Thank A the continued today will our very improve health us. We and
handle session. and open We Ran the which will begin up Erez Operator, Daniel will call now question Q&A the for today. please
